Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.79 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2442344 | 1.00 | PDE10A (0.79) | PDE10APIM1KCNH2 | |
| SCHEMBL2440811 | 0.97 | PDE10A (0.74) | PDE10APIM1KCNH2 | |
| SCHEMBL2440805 | 0.97 | PDE10A (0.74) | PDE10APIM1KCNH2 | |
| SCHEMBL2445481 | 0.88 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2434724 | 0.88 | PDE10A (1.00) | PDE10A | |
| Hydrochloric Acid SCHEMBL2405839 | 0.87 | PDE10A (0.98) | PDE10A | |
| Hydrochloric Acid SCHEMBL14119998 | 0.87 | PDE10A (0.98) | PDE10A | |
| SCHEMBL14120392 | 0.85 | PDE10A (0.94) | PDE10A | |
| SCHEMBL14120391 | 0.85 | PDE10A (0.94) | PDE10A | |
| SCHEMBL14211911 | 0.85 | PDE10A (0.85) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539342-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8969376-B2 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | PDE10A 5/4885PIM1 2301/4885KCNH2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.